26 results on '"Saber, Haleh"'
Search Results
2. Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
3. Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement
4. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products
5. An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
6. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
7. An FDA oncology analysis of immune activating products and first-in-human dose selection
8. Supplementary Table 1 from FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
9. Data from FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
10. An FDA oncology analysis of antibody-drug conjugates
11. Antibody–Drug Conjugate Development
12. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs
13. Antibody–Drug Conjugate Development
14. Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective
15. FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
16. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
17. FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
18. FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
19. U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
20. U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia
21. U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
22. U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
23. FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation
24. Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
25. Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
26. U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.